Impact News +++ Should You Hold Onto Globus Medical Stock in Your Portfolio for Now? (Zacks) +++ GLOBUS MEDICAL Aktie +3,00%

PHARMING Aktie

>PHARMING Aktienkurs

1.264 EUR +1.4% (Tradegate)

Ask: 1.279 EUR / 1250 Stück

Bid: 1.264 EUR / 1270 Stück

Tagesumsatz: 38776 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

PHARMING Aktie über LYNX handeln

Intraday

1 Jahr

>PHARMING Performance

1 Woche: +3,3%

1 Monat: +34,4%

3 Monate: +19,8%

6 Monate: +43,6%

1 Jahr: +83,7%

laufendes Jahr: +35,2%

>PHARMING Aktie

Name:

PHARMING GRP EO-,01

Land:

Niederlande

Sektor:

Gesundheit

ISIN/ Wkn:

NL0010391025 / A1H65A

Symbol/ Ticker:

PHGN (Frankfurt)

Kürzel:

FRA:PHGN, ETR:PHGN, PHGN:GR

Index:

Webseite:

https://www.pharming.com/

Profil:

Pharming Group N.V. is a biopharmaceutical company..
>Volltext..

Marktkapitalisierung:

821.85 Mio. EUR

Unternehmenswert:

831.9 Mio. EUR

Umsatz:

315.51 Mio. EUR

EBITDA:

29.49 Mio. EUR

Nettogewinn:

-7.48 Mio. EUR

Gewinn je Aktie:

-0.01 EUR

Schulden:

120.95 Mio. EUR

Liquide Mittel:

81.59 Mio. EUR

Operativer Cashflow:

27.2 Mio. EUR

Bargeldquote:

1.46

Umsatzwachstum:

21.62%

Gewinnwachstum:

37.85%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

PHARMING

Letzte Datenerhebung:

04.09.25

>PHARMING Kennzahlen

Aktien/ Unternehmen:

Aktien: 685.15 Mio. St.

Frei handelbar: 97.73%

Leerverk. Aktien: 4.92%

Rückkaufquote: -0.39%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 90.83%

Bewertung:

KGV: -

KGV lG: -

KUV: 2.63

KBV: 4.42

PEG-Ratio: -

EV/EBITDA: 28.21

Rentabilität:

Bruttomarge: 88.48%

Gewinnmarge: -2.37%

Operative Marge: 6.2%

Managementeffizenz:

Gesamtkaprendite: -1.93%

Eigenkaprendite: -3.8%

>PHARMING Peer Group

Es sind 19 Aktien bekannt.

>PHARMING Chart & Kurs - Tradegate

>PHARMING News

03.09.25 - 08:03	Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)
	Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025....

02.09.25 - 16:45	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks)
	Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach....

02.09.25 - 10:30	Pharming Group names new finance head (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.09.25 - 07:03	Pharming Group appoints Kenneth Lynard as Chief Financial Officer (GlobeNewswire EN)
	Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025....

22.08.25 - 17:30	Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High? (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 142.3% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

06.08.25 - 17:30	Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 145.8% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

04.08.25 - 08:03	Pharming Group to participate in August investor conference (GlobeNewswire EN)
	Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conference in the month of August:...

31.07.25 - 19:54	Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 11:54	Pharming reports Q2 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 07:03	Pharming Group reports second quarter and first half 2025 financial results and provides business update (GlobeNewswire EN)
	Leiden, the Netherlands, July 31, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025....

24.06.25 - 07:03	Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis (GlobeNewswire EN)
	For media and investors only...

11.06.25 - 17:18	Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders (GlobeNewswire EN)
	Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved....

28.05.25 - 08:03	Pharming Group to participate in June investor conferences (GlobeNewswire EN)
	Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June:...

09.05.25 - 15:39	Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.25 - 16:33	Pharming Group N.V. GAAP EPS of $0.02, revenue of $79.1M misses by $1.82M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.25 - 07:03	Pharming Group reports first quarter 2025 financial results and provides business update (GlobeNewswire EN)
	Leiden, the Netherlands, May 8, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary unaudited financial report for the three months ended March 31, 2025....

30.04.25 - 17:51

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director (GlobeNewswire EN)

Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company's 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company's website under Investors/Shareholder Meetings....

25.04.25 - 15:03

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire EN)

Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation....

24.04.25 - 13:12	NICE issues final guidance endorsing Pharming′s APDS therapy (PBR)
	This recommendation facilitates treating the activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 years and above. The oral therapy is now accessible and funded in The post NICE issues final guidance endorsing Pharming's APDS therapy appeared first on Pharmaceutical Business review....

24.04.25 - 08:03	Pharming Group to report first quarter 2025 financial results on May 8 (GlobeNewswire EN)
	Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ich möchte Österreich gerne zu einer Wall Street des Wissens machen. - Dr. Wolfgang Schüssel

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram